Combined treatment using the DNMT inhibitor decitabine and the HDAC inhibitor vorinostat significantly increased the expression of OCT2 in RCC cell lines, which sensitized these cells to oxaliplatin [204]. The gene discussed is DNMT1; the disease is renal cell carcinoma.